(NASDAQ: ADAG) Adagene's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.65%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 32.44%.
Adagene's earnings in 2026 is -$20,511,005.On average, 8 Wall Street analysts forecast ADAG's earnings for 2026 to be -$44,944,076, with the lowest ADAG earnings forecast at -$72,380,525, and the highest ADAG earnings forecast at -$14,100,102. On average, 7 Wall Street analysts forecast ADAG's earnings for 2027 to be -$62,208,308, with the lowest ADAG earnings forecast at -$115,150,835, and the highest ADAG earnings forecast at -$15,862,615.
In 2028, ADAG is forecast to generate -$47,512,309 in earnings, with the lowest earnings forecast at -$72,380,525 and the highest earnings forecast at -$20,268,897.